+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Erectile Dysfunction - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762919
  • Report
  • April 2019
  • Region: Global
  • 98 Pages
  • VPA Research


  • AnyGen Co Ltd
  • Biozeus Pharmaceutical SA
  • Futura Medical Plc
  • IntelGenx Corp
  • NAL Pharmaceuticals Ltd
  • SK Chemicals Co Ltd

Erectile Dysfunction pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Erectile Dysfunction R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Erectile Dysfunction report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Erectile Dysfunction as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Erectile Dysfunction with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Erectile Dysfunction pipeline Profiled in detail

Key players actively participating in Erectile Dysfunction pipeline are profiled along with their R&D progress in Erectile Dysfunction treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Erectile Dysfunction pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Erectile Dysfunction treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Erectile Dysfunction pipeline and treatment landscape

  • Complete list of drug candidates from discovery to pre-registration phases are analyzed

  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio

  • Detailed drug profiles of Erectile Dysfunction pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed

  • Research and Development progress and trial details, results wherever available, are also included in the Erectile Dysfunction pipeline study

  • All recent news and developments related to Erectile Dysfunction drugs are provided

Note: Product cover images may vary from those shown


  • AnyGen Co Ltd
  • Biozeus Pharmaceutical SA
  • Futura Medical Plc
  • IntelGenx Corp
  • NAL Pharmaceuticals Ltd
  • SK Chemicals Co Ltd

1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019
2. Erectile Dysfunction Disease Overview
3. Erectile Dysfunction R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019
4. Erectile Dysfunction Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History
5. Erectile Dysfunction Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History
6. Company Profiles
6.1. Erectile Dysfunction companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Erectile Dysfunction Activities
7. Recent News Landscape
8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • AnyGen Co Ltd

  • Aprogen Inc

  • Astellas Pharma Inc

  • Biozeus Pharmaceutical SA

  • Can-Fite BioPharma Ltd

  • Dicot AB

  • Druggability Technologies Holdings Ltd

  • Fabre-Kramer Pharmaceuticals Inc

  • Futura Medical Plc

  • Humanetics Corp

  • Initiator Pharma AS

  • IntelGenx Corp

  • Karessa Pharma Holding AB

  • Mezzion Pharma Co Ltd

  • Mitsubishi Tanabe Pharma Corp

  • NAL Pharmaceuticals Ltd

  • Pharmicell Co Ltd

  • Seelos Therapeutics Inc

  • SK Chemicals Co Ltd

  • Suda Pharmaceuticals Ltd

  • Techfields Pharma Co Ltd

  • Tritech Biopharmaceuticals Co Ltd

  • Veru Inc

  • XuanZhu Pharma Co Ltd

Note: Product cover images may vary from those shown